To the Prime Minister, Chancellor of the Exchequer and Secretaries of State and Ministers responsible for Business, Science, Energy and the Environment,

Made by British Bio: UK businesses call on government to turn British biotech into British manufacturing

More than 100 businesses, manufacturers, investors and organisations from across the UK bio-based sector are calling on the UK Government to take action to ensure that biotechnologies invented and developed in Britain can be scaled, manufactured and commercialised in Britain.

Together, the signatories represent over £4.4 billion in combined revenues, and more than 35,000 UK jobs.

This follows on from more than 1000 people signing a petition asking the UK Government to conduct an urgent review of how bio-based products are treated across UK policies, regulations and taxation including how their biogenic carbon is accounted for[1].

We are calling for a fundamental shift in how the UK supports the UK bio-based sector and wider bioeconomy, turning world-leading British science into factories, resilient supply chains, skilled jobs, exports and economic growth here in the UK, while reducing our dependence on imported fossil resources and volatile global supply chains.

The message from industry is simple: Britain has invested in the science. Now we need to capture the manufacturing. We are therefore calling on the Government to back a national ambition: *Made by British Bio* (https://bbia.org.uk/made-by-british-bio/). Our message is simple: Seed in Britain. Scale in Britain. Stay in Britain.

We call on the Government to urgently convene a high-level, cross-government roundtable bringing together Ministers, senior officials, industry leaders and key organisations signing this letter.

Size of the Prize: A £500 billion economic opportunity

The UK's bioeconomy already generates approximately £325 billion in gross value added and supports 6.4 million jobs, making it the fourth largest in Europe[2]. Yet despite these strengths, the UK currently ranks only 21st out of 28 European countries for bioeconomy growth, highlighting the scale of the opportunity being missed[3]. However, with the right investment, industrial strategy and policy support, there is potential to grow its annual economic contribution to £500 billion GVA by 2030[4].

Crucially, this is an opportunity that extends across the whole of the United Kingdom, reaching every nation, region and postcode. From rural communities producing sustainable biomass to industrial clusters developing advanced biomanufacturing capabilities, the bioeconomy can drive economic growth, create skilled jobs, revitalise manufacturing and strengthen local supply chains in communities throughout the country.

---

[1] https://petition.parliament.uk/petitions/767417
[2] https://www.naturefinance.net/wp-content/uploads/2026/10/The-UKs-bioeconomy_a-case-for-building-growth-resilience-and-sustainability-2-1.pdf
[3] https://www.naturefinance.net/wp-content/uploads/2026/10/The-UKs-bioeconomy_a-case-for-building-growth-resilience-and-sustainability-2-1.pdf
[4] From Research to Revenue: The Case for Scaling UK Bio-based

From scientific innovation to reindustrialisation, growth and resilience

Britain has world-leading strengths in engineering biology, industrial biotechnology, AI and advanced manufacturing, supported by established chemicals industries, agricultural resources, regional manufacturing clusters and sophisticated financial markets.

The opportunity is not to build a new economy from scratch, but to reindustrialise the industries Britain already has. Beyond its established applications in human health and medicine, biomanufacturing offers a transformative opportunity across the wider economy. From chemicals, cosmetics and cleaning products to packaging, textiles, food ingredients, low-carbon fuels and construction materials, it can revolutionise how everyday products are made, replacing fossil-derived inputs with renewable biological resources, creating skilled jobs and strengthening domestic supply chains.

Government has committed £2 billion over ten years to engineering biology and the wider bioeconomy[5]. But our scientific leadership is not translating into industrial success. High capital costs, limited scale-up infrastructure, uncertain markets and regulatory frameworks designed around fossil-based industries continue to drive British innovation, investment and manufacturing overseas[6] .

At the same time, geopolitical shocks have exposed the economic risks of dependence on imported fossil resources. Russia's invasion of Ukraine and the subsequent energy crisis alone cost the UK an estimated £183 billion over four years[7]. Developing domestic biomanufacturing capacity offers an opportunity to strengthen economic security while revitalising industrial regions, making better use of existing chemicals clusters, infrastructure, skills and agricultural resources.

Made by British Bio - Seed in Britain. Scale in Britain. Stay in Britain.

We must turn our scientific advantage into industrial strength, delivering economic growth, resilient supply chains and environmental sustainability while ensuring that more of the value created by British innovation stays in Britain.

We welcome the Government's commitments in the Autumn budget supporting entrepreneurs, improving access to finance and encouraging business investment, alongside initiatives such as Scale UK Connect, which aims to help high-growth British businesses access investment, commercial partnerships and international markets. It is essential that engineering biology, industrial biotechnology and bio-based manufacturing businesses can fully benefit from these measures.

But we must go further. Supporting start-ups and attracting investment is only part of the challenge. We must create the conditions for British innovations to be scaled, manufactured and commercialised here in the UK, rather than seeing the economic value, skilled jobs and industrial capabilities move overseas.

This requires a coordinated, long-term approach across Government, industry and investors, built around three priorities:

SEED: turn world-leading British science into investable technologies and companies.
SCALE: give those companies access to the infrastructure, capital, skills and markets required to reach competitive commercial production.
STAY: create the conditions that make Britain the place where those companies choose to manufacture, invest and grow for the long term.

---

[5] https://www.gov.uk/government/publications/national-vision-for-engineering-biology
[6] https://bb-reg-net.org.uk/wp-content/uploads/2025/04/BBREGNET_From-Research-to-Revenue.pdf
[7] https://eciu.net/media/press-releases/2025/budget-cost-of-energy-crisis-exceeds-nhs-englands-annual-health-spending

We ask Government to take four actions

1. Put someone in charge
Establish clear ministerial leadership and cross-government coordination for the UK bioeconomy, bringing together science and innovation, industrial policy, taxation, regulation, energy, agriculture, environment and procurement.

2. Make the UK the best place to scale and manufacture
Rapidly deploy the committed £186 million Engineering Biology Infrastructure Programme and create affordable, open-access routes from laboratory innovation through to commercial production. Alongside this, introduce targeted support for first-of-a-kind UK biomanufacturing so companies choosing where to build first commercial plants have a compelling reason to choose Britain.

3. Level the playing field between fossil and renewable carbon
Review taxation, regulation, carbon accounting and environmental policy to ensure sustainable renewable carbon can compete fairly with virgin fossil carbon. Policy must recognise whole-life environmental performance, including fossil-resource displacement, greenhouse-gas emissions, resource efficiency, circularity, persistence and end-of-life impacts.

4. Create markets for British bio-based products
Use the purchasing power of Government to accelerate early markets. The NHS, central government and the wider public sector purchase billions of pounds of materials, ingredients and manufactured products every year. Where safe and effective UK bio-based alternatives exist, procurement should recognise whole-life environmental and economic value and provide the early demand signals needed to unlock private investment.

A chance for Britain to lead

The opportunity extends well beyond the domestic economy. The UK's G20 Presidency in 2027 provides a platform to shape the international bioeconomy agenda and position Britain as a global leader in sustainable biomanufacturing.

Few countries combine Britain's strengths in science, engineering biology, AI, advanced manufacturing, finance, standards and regulation. Together, these capabilities provide a foundation for the UK to become a global hub for bioeconomy innovation, manufacturing, investment and international collaboration.

But global leadership must be built on industrial strength at home. The companies signing this letter believe Britain has the potential not only to pioneer the next generation of biotechnologies, but to manufacture them, export them and capture their economic value.

From Ambition to Action

We call on the Government to urgently convene a high-level, cross-government roundtable bringing together Ministers, senior officials, industry leaders, investors and key organisations signing this letter.

The roundtable should focus on translating the ambitions of *Made by British Bio* into a coordinated programme of action, identifying immediate opportunities to unlock investment, accelerate scale-up and first-of-a-kind manufacturing, create domestic markets and remove regulatory and fiscal barriers.

Industry stands ready to work with Government to agree clear priorities, responsibilities and practical actions that turn British innovation into British manufacturing, skilled jobs and economic growth.

We are ready to invest, innovate, manufacture and grow. We ask Government to create the conditions for us to do it here in Britain.

Yours Sincerely,



Jen Vanderhoven, CEO, BBIA, and Founder BioRevolution Coalition
Email: Jen.vanderhoven@bbia.org.uk
www.bbia.org.uk
www.biorevolution.uk

SIGNATORIES

17Cicada Ltd
2M Holdings Ltd
A&B Smart Materials
AAVantgarde Bio UK Ltd
Agronomics
Akemi Associates Ltd
Alder BioInsights
Alfaplas Limited
Alternative Proteins Association
Azotic Technologies Ltd
BBIA
Bezos Centre for Sustainable Proteins
Bindethics Ltd
BioBuds
Biome
Biorenewables Development Centre
Britest Limited
British Coatings Federation
Business of Science Ltd
C3 Biotechnologies Ltd
Cellcraft ltd
Celtic Renewables
Chemian Technology Limited
Chemical Business Association
Chestnut Biopolymers Ltd
Clean Food Group Ltd
Cosmetics Cluster UK
CPI
Croda
C-Source Renewables Ltd
Deep Blue Biotech
Eco Ventures Counsel
Ecorem Tech Limited
Ensus UK Ltd
Faraday Partners
FermaPolymers
Frey
Futamura
Gloss Communications
Grantham Centre for Sustainable Futures
Green Rose Chemistry
Holiferm Ltd
Hoxton Farms
iBoxit Limited
Industrial Biotechnology Innovation Catalyst
Impact Laboratories Ltd
Inauvia Limited
Ingenza
Institution of Chemical Engineers
Isomerase Ltd
JunkemBio
Kelpi
Kersia UK
Kit & Kin Ltd
LEAFYCOLL LTD
MarinaTex Limited
Marine Biopolymers Ltd
Meatly
Metisium Ltd
MiAlgae Ltd
MilaK Bio Ltd
Modern Synthesis
Naion Ltd
National Alternative Protein Innovation Centre
Natural Building Systems
Natural Negative
Nature finance
NCIMB Ltd
New Wave Biotech Ltd
nfin bio
Notpla
Optimat Ltd
Parkside Flexibles
Pioneer Group
PlantSea
Potter Clarkson
Protevan Ltd
R3V Tech Ltd
Raven Botanicals
Rees Technical
Renewable Energy Association
RIPCELL Ltd
Roslin Technologies
Society of Chemical Industry
Science Developments Ltd
ScotChem
Shellworks
Sinclair international limited
Soluteq Bioplastics
Sun Bear Biofuture
Switch Biologics Ltd
SymphoRNA
Synthomer plc
THG Labs
Twig Bio
University of Edinburgh
University of Manchester
Valogen Biosciences Ltd
VerdiChem
Woodly
Woolcool
Xampla


BBIA


BioRevolution
COALITION


17CICADA


2M
Group of Companies


A+B
SMART
MATERIALS


AAVANTGARDE


AGRONOMICS


Akemi
STEM Business Growth Solutions


Alder
BioInsights


ALFAPLAS
GROUP SPHERE


apa
Alternative Proteins Association
A COLLER INITIATIVE


Azotic


BEZOS CENTER
FOR SUSTAINABLE PROTEIN


BindEthics


BioBuds


BIOME
BIOPLASTICS


BDC
Biorenewables
Development Centre


Britest


BCF
British Coatings
Federation


Bc
Business of Science
Conference

C3 BIOTECH


Cellcraft


Celtic
Renewables


chemian
TECHNOLOGY


100
YEARS
1923 - 2023
Chemical
Business
Association


Chestnut BioPolymers
MADE ROBUSTLY NOT TO LAST™


CLEAN
FOOD
GROUP


COSMETICS
CLUSTER UK


cpi


CRODA
SMART SCIENCE TO IMPROVE LIVES™




deep
blue
BIOTECH


eco
ventures
counsel


ECOREM TECH


ensus


FARADAY PARTNERS


FermaPolymers


FREY
GROWING THE UK BIOECONOMY


FUTAMURA


gloss
communications


Grantham
Centre
for Sustainable Futures
University of
Sheffield



GREEN ROSE
CHEMISTRY


holiferm


HOXTON
FARMS


iBOXiT


INDUSTRIAL
BIOTECHNOLOGY
INNOVATION
CATALYST


impact solutions


ingenza


IChemE
ADVANCING
CHEMICAL
ENGINEERING
WORLDWIDE


ISOMERASE
Health and Sustainability through Biotechnology


JunkemBio
Green science, infinite value


kelpi


kersia


KIT & KIN
PROTECTING YOUR WORLD, NATURALLY


LeafyColl


MARINATEX


MBL
MARINE BIOPOLYMERS


meatly


METISIUM


MiAlgae


miiaK


ModernSynthesis


NAIGN


National Alternative
Protein Innovation
Centre (NAPIC)


Natural
Building
Systems


Natural
Negative


NATURE
FINANCE


NCIMB


NEW
WAVE
BIOTECH


nfin


Notpla


optimat
THE KNOWLEDGE EXPERTS


parkside


Pioneer
Since 2003


plantsea


Potter
Clarkson


protevan®


R3V
TECH


RAVEN
BOTANICALS


REES TECHNICAL
ENGINEERING A BETTER WORLD


REA
THE ASSOCIATION
FOR RENEWABLE ENERGY
& CLEAN TECHNOLOGY


RIPCELL


ROSLIN
Technologies


SCI
where science
meets business


Science Developments Ltd


ScotChem


SHELLWORKS


Sinclair


SUN BEAR
BIOFUTURE


Switch
BiOlogics


SymphoRNA


synthomer


THG / LABS
Acheson


tw:g


THE UNIVERSITY
of EDINBURGH


MANCHESTER
1824
The University of Manchester


valogen


VERDICHEM


WOODLY


WOOLCOOL


Xampla